spacer
home > ebr > winter 2019 > the impact of brexit on the pharma industry
PUBLICATIONS
European Biopharmaceutical Review

The Impact of Brexit on the Pharma Industry

Brexit: with negotiations still ongoing at the time of writing and the situation changing almost daily, it is not surprising that concerns are elevated in pharmaceutical circles – both within the UK and across mainland Europe. Looking at the potential impact of Brexit and the import and export of products between the UK and the EU every month, an important question is: how will this trade keep flowing without major disruption? Everyone is aware of uncertainty at the moment – not just for the UK, but also for the EU manufacturers supplying into it – but, as negotiations continue, industry should prepare itself for the possibility of change.

This is largely attributable to the UK government’s ‘red lines’: according to these, people will not have free movement and being able to freely negotiate global trade deals is required. Additionally, reducing contributions to the EU budget is desired, as well as being free from its courts of justice, and, finally, regulatory autonomy requirements.

If these red lines remain inflexible, but obstacles stalling the negotiation can be overcome, one scenario is that the UK could end up with a Canadian-style deal with the EU, where the country has almost completely tariff-free trade with the EU, but with greater regulatory barriers than member states.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lynne Byers is the Executive Director of Pharmaceuticals and Biotechnology at NSF International. She graduated in chemistry in 1985. During her career, which spans more than 35 years, Lynne has gained extensive knowledge in the pharmaceutical manufacturing management and quality assurance (QA) areas, working as Global Head (Vice President) of external supply operations QA for Novartis and as Head of Inspectorate and Licensing for the MHRA, before joining NSF International in 2017. Her areas of expertise include QP training, packaging and labelling control GMP legislation, API manufacture and control, auditing and self-inspection skills, education of auditors, supply chain distribution, quality management of pharmaceutical suppliers, quality management of contract manufacturers, and affiliate quality assurance.
spacer
Lynne Byers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TrialScope Taps Industry Veteran as CTO

JERSEY CITY, NJ, July 29, 2019 – TrialScope, the global leader in clinical trial transparency and compliance solutions, announces the appointment of Ruben Echandy as Chief Technology Officer.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement